Static Chart Moleculin Biotech, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
5.08 ^USD	+0.99%		+6.72%	-60.55%

May. 15	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	CI
May. 13	Transcript : Moleculin Biotech, Inc., Q1 2024 Earnings Call, May 13, 2024

Duration

Period